| scholarly article | Q13442814 |
| P50 | author | Richard M Martin | Q52574555 |
| P2093 | author name string | C Davies | |
| D Gunnell | |||
| D Irvine | |||
| L Wise | |||
| P2860 | cites work | Smoking at age 18-20 and suicide during 26 years of follow-up-how can the association be explained? | Q44697406 |
| Factors influencing the development and amelioration of suicidal thoughts in the general population. Cohort study | Q50751228 | ||
| Cigarette smoking and suicidal behaviour: results from a 25-year longitudinal study | Q59187226 | ||
| Cigarettes and suicide: a prospective study of 50,000 men | Q24544041 | ||
| Smoking and suicide: a brief overview | Q24655785 | ||
| Varenicline improves mood and cognition during smoking abstinence | Q30483957 | ||
| Validation of information recorded on general practitioner based computerised data resource in the United Kingdom | Q33539292 | ||
| Suicide, deprivation, and unemployment: record linkage study | Q33852359 | ||
| Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study | Q33853140 | ||
| Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial | Q33997418 | ||
| Varenicline for tobacco dependence | Q34222136 | ||
| Use of the UK General Practice Research Database for pharmacoepidemiology | Q35802395 | ||
| A preliminary benefit-risk assessment of varenicline in smoking cessation | Q37399078 | ||
| Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. | Q38405712 | ||
| Might stopping smoking reduce injury death risks? A meta-analysis of randomized, controlled trials | Q41612451 | ||
| Nicotine, alcohol and drug dependence and psychiatric comorbidity. Results of a national household survey | Q43786714 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | database | Q8513 |
| suicide | Q10737 | ||
| varenicline | Q411330 | ||
| suicide prevention | Q3298118 | ||
| suicide risk | Q47319077 | ||
| P304 | page(s) | b3805 | |
| P577 | publication date | 2009-10-01 | |
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database | |
| P478 | volume | 339 |
| Q37395553 | A Double-Blind Placebo-Controlled Randomized Trial of Varenicline for Smokeless Tobacco Dependence in India |
| Q37807401 | A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation |
| Q48065103 | A comparison of neuropsychiatric adverse events during early treatment with varenicline or a nicotine patch |
| Q37818134 | Adverse effects and tolerability of medications for the treatment of tobacco use and dependence |
| Q34049603 | Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals |
| Q26747804 | Are Smoking Cessation Treatments Associated with Suicidality Risk? An Overview |
| Q34277168 | BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. |
| Q28267175 | Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study |
| Q34144971 | Cardiovascular and neuropsychiatric safety of varenicline and bupropion compared with nicotine replacement therapy for smoking cessation: study protocol of a retrospective cohort study using the QResearch general practice database |
| Q43892186 | Characteristics of COPD Smokers and Effectiveness and Safety of Smoking Cessation Medications |
| Q37376724 | Cognition as a therapeutic target in late-life depression: Potential for nicotinic therapeutics |
| Q24635465 | Depressogenic effects of medications: a review |
| Q51035685 | Did the introduction of varenicline in England substitute for or add to the use of other smoking cessation medications? |
| Q48908945 | Does Smoking Cessation Cause Depression and Anxiety? Findings from the ATTEMPT Cohort |
| Q48176478 | Effect of varenicline on individual nicotine withdrawal symptoms: a combined analysis of eight randomized, placebo-controlled trials. |
| Q45065349 | Effectiveness of varenicline as an aid to smoking cessation in primary care: an observational study. |
| Q45934405 | Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study |
| Q37347937 | Effects of varenicline, nicotine or placebo on depressive symptoms in postmenopausal smokers. |
| Q58659391 | Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels |
| Q35667964 | Examining antidepressant drug response by smoking status: why is it important and how often is it done? |
| Q36948579 | Factors influencing sustainable efficacy of smoking cessation treatment with varenicline beyond nine months |
| Q38636469 | Feeding Two Birds with One Scone: The Case of Varenicline |
| Q24658591 | Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial |
| Q26772025 | HIV and smoking: associated risks and prevention strategies |
| Q28086911 | Health-care interventions to promote and assist tobacco cessation: a review of efficacy, effectiveness and affordability for use in national guideline development |
| Q84029332 | Helping the "hard-core" smokers |
| Q30441131 | How Can We Use Our Knowledge of Alcohol-Tobacco Interactions to Reduce Alcohol Use? |
| Q38720906 | How do smoking cessation medicines compare with respect to their neuropsychiatric safety? A protocol for a systematic review, network meta-analysis and cost-effectiveness analysis |
| Q24200887 | Interventions for smoking cessation and reduction in individuals with schizophrenia |
| Q36085309 | Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances |
| Q92162923 | Long-term effectiveness and safety of varenicline and nicotine replacement therapy in people with neurodevelopmental disorders: A prospective cohort study |
| Q36724460 | Longitudinal associations between smoking cessation medications and alcohol consumption among smokers in the International Tobacco Control Four Country survey |
| Q34014716 | Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. |
| Q38135358 | Managing tobacco use: the neglected cardiovascular disease risk factor |
| Q37473457 | Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders |
| Q50748859 | Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System |
| Q45025537 | Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England |
| Q28277165 | New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline? |
| Q24185773 | Nicotine receptor partial agonists for smoking cessation |
| Q24200322 | Nicotine receptor partial agonists for smoking cessation |
| Q24234065 | Nicotine receptor partial agonists for smoking cessation |
| Q24235456 | Nicotine receptor partial agonists for smoking cessation |
| Q24634536 | Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis |
| Q36987118 | Nicotine vaccines to assist with smoking cessation: current status of research |
| Q37651602 | Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature |
| Q28078315 | Non-psychotropic medication and risk of suicide or attempted suicide: a systematic review |
| Q30408254 | Pharmacologic Agents for Tobacco Dependence Treatment: 2011 Update |
| Q24202961 | Pharmacological interventions for smoking cessation: an overview and network meta-analysis |
| Q34366802 | Pharmacotherapies and harm-reduction options for the treatment of tobacco dependence |
| Q42576248 | Pharmacotherapy for smoking |
| Q37863092 | Pharmacotherapy for smoking cessation: current advances and research topics |
| Q33582051 | Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice |
| Q37984281 | Preventive aspects in peripheral artery disease |
| Q43673372 | Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand |
| Q34617901 | Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis |
| Q36590602 | Quitting smoking before and after varenicline: a population study based on two representative samples of US smokers |
| Q34803655 | Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice. |
| Q34285010 | Reporting of drug induced depression and fatal and non-fatal suicidal behaviour in the UK from 1998 to 2011. |
| Q28083649 | Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis |
| Q38235950 | Risks and benefits of (pharmaco)epidemiology |
| Q37589870 | Role of nicotine receptor partial agonists in tobacco cessation. |
| Q33467634 | Safety of Varenicline for Smoking Cessation in Psychiatric and Addicts Patients |
| Q30467200 | Selective α4β2 nicotinic acetylcholine receptor agonists target epigenetic mechanisms in cortical GABAergic neurons |
| Q40587312 | Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis |
| Q40456297 | Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis. |
| Q37838644 | Sleep, Serotonin, and Suicide in Japan |
| Q26785461 | Smoking Use and Cessation Among People with Serious Mental Illness |
| Q34157608 | Smoking cessation after brain damage does not lead to increased depression: implications for understanding the psychiatric complications of varenicline |
| Q22299201 | Smoking cessation and COPD |
| Q64954659 | Smoking cessation for people with severe mental illness (SCIMITAR+): a pragmatic randomised controlled trial. |
| Q35491463 | Smoking cessation in Asians: focus on varenicline |
| Q38178774 | Smoking cessation in patients with respiratory disease: existing treatments and future directions |
| Q37248189 | Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study |
| Q51841457 | Stop-smoking support: considerations for community nurses |
| Q37868003 | Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned? |
| Q34306544 | Strategies to help a smoker who is struggling to quit |
| Q48361084 | Study suggests varenicline safe and effective among adults with stable depression |
| Q21089921 | Suicidal behavior and depression in smoking cessation treatments |
| Q42316790 | The Food and Drug Administration and varenicline: should risk communication be improved? |
| Q51597754 | The nicotinic acetylcholine receptor as a target for antidepressant drug development |
| Q35226577 | Tobacco use and cessation for cancer survivors: an overview for clinicians |
| Q38736026 | Treatment with bupropion and varenicline for smoking cessation and the risk of acute cardiovascular events and injuries: a Swedish case-crossover study |
| Q38729731 | Trends in utilization of smoking cessation agents before and after the passage of FDA boxed warning in the United States |
| Q34506003 | Update in addiction medicine for the generalist |
| Q34566194 | Usage patterns of stop smoking medications in Australia, Canada, the United Kingdom, and the United States: findings from the 2006-2008 International Tobacco Control (ITC) Four Country Survey |
| Q48663247 | Use of the Patient Health Questionnaire‐2 to Predict Suicidal Ideations in Patients Taking Varenicline |
| Q44249993 | Use of varenicline versus bupropion and risk of psychiatric adverse events |
| Q36988030 | Validation of suicide and self-harm records in the Clinical Practice Research Datalink |
| Q28554332 | Varenicline and Risk of Self-Harm: A Nested Case-Control Study |
| Q28646213 | Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study |
| Q28255130 | Varenicline as a Cause of Suicidal Outcomes |
| Q38797685 | Varenicline for smoking cessation and reduction in people with severe mental illnesses: systematic review and meta-analysis |
| Q34190097 | Varenicline for tobacco dependence: panacea or plight? |
| Q50302705 | Varenicline in Autistic Disorder: Hypothesis and Case Report of Single-Patient Crossover |
| Q37762828 | Varenicline in smoking cessation |
| Q42953739 | Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries |
| Q37694553 | Varenicline use in patients with mental illness: an update of the evidence |
| Q34546833 | Varenicline, smoking cessation, and neuropsychiatric adverse events |
| Q37079004 | Varenicline-induced psychotic depressive episode in a patient with bipolar disorder |
| Q37682886 | Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation |
| Q84900930 | Varenicline: quantifying the risk |
Search more.